{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:09:19Z","timestamp":1783789759648,"version":"3.55.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO 6855\/1-1"],"award-info":[{"award-number":["HO 6855\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR267 (No. 403584255)"],"award-info":[{"award-number":["SFB TRR267 (No. 403584255)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR267 (No. 403584255)"],"award-info":[{"award-number":["SFB TRR267 (No. 403584255)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is a multi-organ disease, caused by mutations in the <jats:italic>GLA<\/jats:italic> gene and leading to a progressive accumulation of glycosphingolipids due to enzymatic absence or malfunction of the encoded alpha-galactosidase A. Since pathomechanisms are not yet fully understood and available treatments are not efficient for all mutation types and tissues, further research is highly needed. This research involves many different model types, with significant effort towards the establishment of an in vivo model. However, these models did not replicate the variety of symptoms observed in patients. As an alternative strategy, patient-derived somatic cells as well as patient-independent cell lines were used to model specific aspects of the disease in vitro. Fabry disease patients present different phenotypes according to the mutation and the level of residual enzyme activity, pointing to the necessity of personalized disease modeling. With the advent of induced pluripotent stem cells, the derivation of a multitude of disease-affected cell types became possible, even in a patient-specific and mutation-specific manner. Only recently, three-dimensional Fabry disease models were established that even more closely resemble the native tissue of investigated organs and will bring research closer to the in vivo situation. This review provides an overview of human in vitro models and their achievements in unravelling the Fabry disease pathomechanism as well as in elucidating current and future treatment strategies.<\/jats:p>","DOI":"10.1186\/s12967-024-05756-w","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:02:21Z","timestamp":1729774941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Human in vitro models for Fabry disease: new paths for unravelling disease mechanisms and therapies"],"prefix":"10.1186","volume":"22","author":[{"given":"Carla","family":"Borisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"B\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5457-0626","authenticated-orcid":false,"given":"Jeannine","family":"Hoepfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"4","key":"5756_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson W. A case of \u201cangeio-keratoma.\u201d Br J Dermatol. 1898;10(4):113\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.1898.tb16317.x.","journal-title":"Br J Dermatol"},{"key":"5756_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1947.tb06596.x","author":"AWM Pompen","year":"1947","unstructured":"Pompen AWM, Ruiter M, Wyers HJG. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand. 1947. https:\/\/doi.org\/10.1111\/j.0954-6820.1947.tb06596.x.","journal-title":"Acta Med Scand"},{"issue":"1","key":"5756_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph. 1898;43(1):187\u2013200. https:\/\/doi.org\/10.1007\/BF01986897.","journal-title":"Arch Dermatol Syph"},{"key":"5756_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-90-481-9033-1","volume-title":"Fabry disease","author":"D Elstein","year":"2010","unstructured":"Elstein D, Altarescu G, Beck M. Fabry disease. Heidelberg: Springer, Netherlands; 2010."},{"issue":"3","key":"5756_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the fabry outcome survey. Eur J Clin Invest. 2004;34(3):236\u201342. https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01309.x.","journal-title":"Eur J Clin Invest"},{"key":"5756_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/2326409816661352","author":"A Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez A, Politei J. Cardiac manifestation of fabry disease: from hypertrophic cardiomyopathy to early diagnosis and treatment in patients without left ventricular hypertrophy. J Inborn Errors Metab Screen. 2016. https:\/\/doi.org\/10.1177\/2326409816661352.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"2","key":"5756_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08002.x.","journal-title":"Br J Dermatol"},{"key":"5756_CR8","doi-asserted-by":"publisher","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30","DOI":"10.1186\/1750-1172-5-30"},{"key":"5756_CR9","doi-asserted-by":"publisher","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354. https:\/\/doi.org\/10.1001\/jama.281.3.249","DOI":"10.1001\/jama.281.3.249"},{"issue":"1","key":"5756_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, et al. High incidence of later-onset Fabry disease revealed by newborn screening*. Am J Human Gen. 2006;79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601.","journal-title":"Am J Human Gen"},{"issue":"2","key":"5756_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20070479","volume":"406","author":"S Ishii","year":"2007","unstructured":"Ishii S, et al. Mutant \u03b1-galactosidase a enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J. 2007;406(2):285\u201395. https:\/\/doi.org\/10.1042\/BJ20070479.","journal-title":"Biochem J"},{"key":"5756_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094434","author":"O Azevedo","year":"2021","unstructured":"Azevedo O, et al. Fabry disease and the heart: a comprehensive review. MDPI. 2021. https:\/\/doi.org\/10.3390\/ijms22094434.","journal-title":"MDPI"},{"issue":"2","key":"5756_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN. The molecular defect leading to fabry disease: Structure of human \u03b1-galactosidase. J Mol Biol. 2004;337(2):319\u201335. https:\/\/doi.org\/10.1016\/j.jmb.2004.01.035.","journal-title":"J Mol Biol"},{"key":"5756_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.029","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. Elsevier. 2014. https:\/\/doi.org\/10.1016\/j.jns.2014.06.029.","journal-title":"Elsevier"},{"issue":"4","key":"5756_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M. Cardiac manifestations of anderson-Fabry disease in children and adolescents. Acta Paediatrica, Int J Paedia. 2008;97(4):463\u20139. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00700.x.","journal-title":"Acta Paediatrica, Int J Paedia"},{"issue":"5","key":"5756_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF01606034","volume":"417","author":"M Elleder","year":"1990","unstructured":"Elleder M, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449\u201355. https:\/\/doi.org\/10.1007\/BF01606034.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"5756_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61589-5","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008. https:\/\/doi.org\/10.1016\/S0140-6736(08)61589-5.","journal-title":"Lancet"},{"key":"5756_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.10.007","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, et al. The management and treatment of children with Fabry disease A United States-based perspective. Academic Press Inc. 2016. https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.007.","journal-title":"Academic Press Inc"},{"issue":"3","key":"5756_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder AC, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94(3):319\u201325. https:\/\/doi.org\/10.1016\/j.ymgme.2008.03.003.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"5756_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with fabry disease. J Med Genet. 2015;52(5):353\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102797.","journal-title":"J Med Genet"},{"key":"5756_CR21","doi-asserted-by":"publisher","DOI":"10.1086\/318809","author":"CM Eng","year":"2001","unstructured":"Eng CM, et al. A Phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Human Gen. 2001. https:\/\/doi.org\/10.1086\/318809.","journal-title":"Am J Human Gen"},{"issue":"13","key":"5756_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","volume":"95","author":"M Imbriaco","year":"2009","unstructured":"Imbriaco M, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective longterm cardiac magnetic resonance imaging study. Heart. 2009;95(13):1103\u20137. https:\/\/doi.org\/10.1136\/hrt.2008.162800.","journal-title":"Heart"},{"key":"5756_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51805-6","author":"K Xiao","year":"2019","unstructured":"Xiao K, et al. Circulating microRNAs in Fabry disease. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-019-51805-6.","journal-title":"Sci Rep"},{"key":"5756_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020320","author":"M Umer","year":"2023","unstructured":"Umer M, Kalra DK. Treatment of Fabry disease: established and emerging therapies. MDPI. 2023. https:\/\/doi.org\/10.3390\/ph16020320.","journal-title":"MDPI"},{"issue":"6","key":"5756_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/nejmoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355. https:\/\/doi.org\/10.1056\/nejmoa1510198.","journal-title":"N Engl J Med"},{"issue":"4","key":"5756_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","volume":"96","author":"K Sugawara","year":"2009","unstructured":"Sugawara K, et al. Molecular interaction of imino sugars with human \u03b1-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol Genet Metab. 2009;96(4):233\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.017.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"5756_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","volume":"27","author":"F DeRosa","year":"2019","unstructured":"DeRosa F, et al. Improved efficacy in a Fabry disease model using a systemic mrna liver depot system as compared to enzyme replacement therapy. Mol Ther. 2019;27(4):878\u201389. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.001.","journal-title":"Mol Ther"},{"key":"5756_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.214","author":"FM Platt","year":"2018","unstructured":"Platt FM. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Publ Group. 2018. https:\/\/doi.org\/10.1038\/nrd.2017.214.","journal-title":"Nat Publ Group"},{"issue":"4","key":"5756_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard N, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103(4):703\u201311. https:\/\/doi.org\/10.1002\/cpt.790.","journal-title":"Clin Pharmacol Ther"},{"key":"5756_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21371-5","author":"A Khan","year":"2021","unstructured":"Khan A, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-21371-5.","journal-title":"Nat Commun"},{"key":"5756_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.6.2540","author":"T Ohshima","year":"1997","unstructured":"Ohshima T, et al. Galactosidase a deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA. 1997. https:\/\/doi.org\/10.1073\/pnas.94.6.2540.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5756_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015422","author":"K Klug","year":"2023","unstructured":"Klug K, et al. Endothelial cell dysfunction and hypoxia as potential mediators of pain in Fabry disease: a human-murine translational approach. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242015422.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5756_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jb\/mvq125","volume":"149","author":"C Shiozuka","year":"2011","unstructured":"Shiozuka C, et al. Increased globotriaosylceramide levels in a transgenic mouse expressing human \u03b11,4-galactosyltransferase and a mouse model for treating Fabry disease. J Biochem. 2011;149(2):161\u201370. https:\/\/doi.org\/10.1093\/jb\/mvq125.","journal-title":"J Biochem"},{"issue":"3","key":"5756_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","volume":"1690","author":"S Ishii","year":"2004","unstructured":"Ishii S, Yoshioka H, Mannen K, Kulkarni AB, Fan JQ. Transgenic mouse expressing human mutant \u03b1-galactosidase a in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta Mol Basis Dis. 2004;1690(3):250\u20137. https:\/\/doi.org\/10.1016\/j.bbadis.2004.07.001.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5756_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99171","author":"JJ Miller","year":"2018","unstructured":"Miller JJ, et al. Neuropathic pain in a Fabry disease rat model. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.99171.","journal-title":"JCI Insight"},{"issue":"1","key":"5756_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1096\/fj.201800771R","volume":"33","author":"JJ Miller","year":"2019","unstructured":"Miller JJ, et al. \u03b1-galactosidase a-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. FASEB J. 2019;33(1):418\u201329. https:\/\/doi.org\/10.1096\/fj.201800771R.","journal-title":"FASEB J"},{"issue":"5","key":"5756_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22052381","volume":"22","author":"HY Song","year":"2021","unstructured":"Song HY, et al. Reversal of the inflammatory responses in fabry patient ipsc-derived cardiovascular endothelial cells by crispr\/cas9-corrected mutation. Int J Mol Sci. 2021;22(5):1\u201319. https:\/\/doi.org\/10.3390\/ijms22052381.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5756_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","volume":"82","author":"T L\u00fccke","year":"2004","unstructured":"L\u00fccke T, H\u00f6ppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004;82(1):93\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2004.01.011.","journal-title":"Mol Genet Metab"},{"key":"5756_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113134","author":"V Rickert","year":"2019","unstructured":"Rickert V, Kramer D, Schubert AL, Sommer C, Wischmeyer E, \u00dc\u00e7eyler N. Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. Exp Neurol. 2019. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113134.","journal-title":"Exp Neurol"},{"issue":"6","key":"5756_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00428-008-0586-9","volume":"452","author":"J Keslov\u00e1-Vesel\u00edkov\u00e1","year":"2008","unstructured":"Keslov\u00e1-Vesel\u00edkov\u00e1 J, et al. Replacement of \u03b1-galactosidase a in Fabry disease: Effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch. 2008;452(6):651\u201365. https:\/\/doi.org\/10.1007\/s00428-008-0586-9.","journal-title":"Virchows Arch"},{"issue":"2\u20133","key":"5756_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10545-006-0287-y","volume":"29","author":"Y Suzuki","year":"2006","unstructured":"Suzuki Y. \u03b2-Galactosidase deficiency: an approach to chaperone therapy. J Inherit Metab Dis. 2006;29(2\u20133):471\u20136. https:\/\/doi.org\/10.1007\/s10545-006-0287-y.","journal-title":"J Inherit Metab Dis"},{"key":"5756_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095105","author":"M Monticelli","year":"2022","unstructured":"Monticelli M, et al. Drug repositioning for Fabry disease: acetylsalicylic acid potentiates the stabilization of lysosomal alpha-galactosidase by pharmacological chaperones. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23095105.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"5756_CR43","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford RWD, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27(19):3392\u2013403. https:\/\/doi.org\/10.1093\/hmg\/ddy248.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5756_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jmv.10467","volume":"71","author":"J D\u2019Costa","year":"2003","unstructured":"D\u2019Costa J, et al. HIV-2 derived lentiviral vectors: gene transfer in Parkinson\u2019s and Fabry disease models in vitro. J Med Virol. 2003;71(2):173\u201382. https:\/\/doi.org\/10.1002\/jmv.10467.","journal-title":"J Med Virol"},{"issue":"1","key":"5756_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA. Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2013.02.003.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"5756_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ymgme.2019.05.009","volume":"127","author":"N \u00dc\u00e7eyler","year":"2019","unstructured":"\u00dc\u00e7eyler N, Urlaub D, Mayer C, Uehlein S, Held M, Sommer C. Tumor necrosis factor-\u03b1 links heat and inflammation with Fabry pain. Mol Genet Metab. 2019;127(3):200\u20136. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.009.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"5756_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0217780","volume":"14","author":"AN Crivaro","year":"2019","unstructured":"Crivaro AN, et al. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and gaucher disease. PLoS ONE. 2019;14(5):1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0217780.","journal-title":"PLoS ONE"},{"issue":"1","key":"5756_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/eji.201545725","volume":"46","author":"CS Pereira","year":"2016","unstructured":"Pereira CS, Sa-Miranda C, De Libero G, Mori L, Macedo MF. Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner. Eur J Immunol. 2016;46(1):147\u201353. https:\/\/doi.org\/10.1002\/eji.201545725.","journal-title":"Eur J Immunol"},{"issue":"January","key":"5756_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cca.2018.02.021","volume":"481","author":"L Ferri","year":"2018","unstructured":"Ferri L, et al. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ. Clin Chim Acta. 2018;481(January):25\u201333. https:\/\/doi.org\/10.1016\/j.cca.2018.02.021.","journal-title":"Clin Chim Acta"},{"issue":"1\u20132","key":"5756_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ymgme.2007.06.003","volume":"92","author":"JS Shen","year":"2007","unstructured":"Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab. 2007;92(1\u20132):137\u201344. https:\/\/doi.org\/10.1016\/j.ymgme.2007.06.003.","journal-title":"Mol Genet Metab"},{"key":"5756_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021095","author":"M Monticelli","year":"2023","unstructured":"Monticelli M, et al. Curcumin has beneficial effects on lysosomal alpha-galactosidase: potential implications for the cure of Fabry disease. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021095.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5756_CR52","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","volume":"56","author":"M Lenders","year":"2019","unstructured":"Lenders M, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56(8):548\u201356. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106005.","journal-title":"J Med Genet"},{"issue":"9","key":"5756_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mgg3.864","volume":"7","author":"P Li","year":"2019","unstructured":"Li P, et al. Functional evaluation of a novel GLA causative mutation in Fabry disease. Mol Genet Genomic Med. 2019;7(9):1\u20138. https:\/\/doi.org\/10.1002\/mgg3.864.","journal-title":"Mol Genet Genomic Med"},{"key":"5756_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100926","author":"F Consolato","year":"2022","unstructured":"Consolato F, et al. \u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response. Mol Genet Metab Rep. 2022. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100926.","journal-title":"Mol Genet Metab Rep."},{"key":"5756_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122089","author":"HY Song","year":"2016","unstructured":"Song HY, et al. Using CRISPR\/Cas9-mediated GLA gene knockout as an in vitro drug screening model for fabry disease. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17122089.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5756_CR56","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bbagen.2013.12.018","volume":"1840","author":"G Andreotti","year":"2014","unstructured":"Andreotti G, Citro V, Correra A, Cubellis MV. A thermodynamic assay to test pharmacological chaperones for Fabry disease. Biochim Biophys Acta Gen Subj. 2014;1840(3):1214\u201324. https:\/\/doi.org\/10.1016\/j.bbagen.2013.12.018.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"5756_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104824","author":"LCS Castellanos","year":"2020","unstructured":"Castellanos LCS, Rozenfeld P, Gatto RG, Reisin RC, Uchitel OD, Weissmann C. Upregulation of ASIC1a channels in an in vitro model of Fabry disease. Neurochem Int. 2020. https:\/\/doi.org\/10.1016\/j.neuint.2020.104824.","journal-title":"Neurochem Int"},{"key":"5756_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-012-0311-3","author":"JM Lorenzen","year":"2013","unstructured":"Lorenzen JM, et al. Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. Basic Res Cardiol. 2013. https:\/\/doi.org\/10.1007\/s00395-012-0311-3.","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"5756_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/BF00227722","volume":"85","author":"M Inagaki","year":"1993","unstructured":"Inagaki M, Katsumoto T, Nanba E, Ohno K, Suehiro S, Takeshita K. Lysosomal glycosphingolipid storage in chloroquine-induced \u03b1-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease. Acta Neuropathol. 1993;85(3):272\u20139. https:\/\/doi.org\/10.1007\/BF00227722.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"5756_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.kint.2018.08.033","volume":"95","author":"JJ Kang","year":"2019","unstructured":"Kang JJ, et al. \u03b1-galactosidase a deficiency promotes von willebrand factor secretion in models of Fabry disease. Kidney Int. 2019;95(1):149\u201359. https:\/\/doi.org\/10.1016\/j.kint.2018.08.033.","journal-title":"Kidney Int"},{"key":"5756_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.789142","author":"S Pollmann","year":"2021","unstructured":"Pollmann S, Scharnetzki D, Manikowski D, Lenders M, Brand E. Endothelial dysfunction in fabry disease is related to glycocalyx degradation. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.789142.","journal-title":"Front Immunol"},{"issue":"6","key":"5756_CR62","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10545-012-9472-3","volume":"35","author":"D Marchesan","year":"2012","unstructured":"Marchesan D, Cox TM, Deegan PB. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. J Inherit Metab Dis. 2012;35(6):1107\u201317. https:\/\/doi.org\/10.1007\/s10545-012-9472-3.","journal-title":"J Inherit Metab Dis"},{"key":"5756_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063506","author":"MC Liebau","year":"2013","unstructured":"Liebau MC, et al. Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0063506.","journal-title":"PLoS ONE"},{"issue":"5","key":"5756_CR64","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.33594\/000000077","volume":"52","author":"F Braun","year":"2019","unstructured":"Braun F, et al. Enzyme replacement therapy clears GB3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling. Cell Physiol Biochem. 2019;52(5):1139\u201350. https:\/\/doi.org\/10.33594\/000000077.","journal-title":"Cell Physiol Biochem"},{"key":"5756_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157782","author":"F Braun","year":"2023","unstructured":"Braun F, et al. Accumulation of \u03b1-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI157782.","journal-title":"J Clin Invest"},{"issue":"12","key":"5756_CR66","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/jcp.25807","volume":"232","author":"T Squillaro","year":"2017","unstructured":"Squillaro T, et al. Impact of lysosomal storage disorders on biology of mesenchymal stem cells: evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase a (GLA) enzymes. J Cell Physiol. 2017;232(12):3454\u201367. https:\/\/doi.org\/10.1002\/jcp.25807.","journal-title":"J Cell Physiol"},{"issue":"1\u20132","key":"5756_CR67","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ymgme.2016.07.010","volume":"119","author":"CR Kaneski","year":"2016","unstructured":"Kaneski CR, Brady RO, Hanover JA, Schueler UH. Development of a model system for neuronal dysfunction in Fabry disease. Mol Genet Metab. 2016;119(1\u20132):144\u201350. https:\/\/doi.org\/10.1016\/j.ymgme.2016.07.010.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"5756_CR68","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019.","journal-title":"Cell"},{"key":"5756_CR69","doi-asserted-by":"publisher","unstructured":"Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K. Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development.\u00a0Physiol Rev. 2019;99(1):79\u2013114. https:\/\/doi.org\/10.1152\/physrev.00039.2017.","DOI":"10.1152\/physrev.00039.2017"},{"issue":"4","key":"5756_CR70","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ymgme.2013.06.003","volume":"109","author":"S Kawagoe","year":"2013","unstructured":"Kawagoe S, et al. Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). Mol Genet Metab. 2013;109(4):386\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2013.06.003.","journal-title":"Mol Genet Metab"},{"key":"5756_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2024.103404","author":"C Jahn","year":"2024","unstructured":"Jahn C, et al. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation. Stem Cell Res. 2024. https:\/\/doi.org\/10.1016\/j.scr.2024.103404.","journal-title":"Stem Cell Res"},{"issue":"1","key":"5756_CR72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jimd.12567","volume":"46","author":"T Miyajima","year":"2023","unstructured":"Miyajima T, et al. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease. J Inherit Metab Dis. 2023;46(1):143\u201352. https:\/\/doi.org\/10.1002\/jimd.12567.","journal-title":"J Inherit Metab Dis"},{"key":"5756_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051480","author":"Y Chien","year":"2018","unstructured":"Chien Y, et al. Inhibition of arachidonate 12\/15-lipoxygenase improves \u03b1-galactosidase efficacy in iPSC-derived cardiomyocytes from fabry patients. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19051480.","journal-title":"Int J Mol Sci"},{"key":"5756_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102633","author":"HS Do","year":"2020","unstructured":"Do HS, et al. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102633.","journal-title":"EBioMedicine"},{"issue":"10","key":"5756_CR75","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","volume":"53","author":"JW Kim","year":"2021","unstructured":"Kim JW, et al. Human kidney organoids reveal the role of glutathione in Fabry disease. Exp Mol Med. 2021;53(10):1580\u201391. https:\/\/doi.org\/10.1038\/s12276-021-00683-y.","journal-title":"Exp Mol Med"},{"key":"5756_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2018.07.246","author":"Y Kuramoto","year":"2018","unstructured":"Kuramoto Y, et al. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient. J Mol Cell Cardiol. 2018. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.07.246.","journal-title":"J Mol Cell Cardiol"},{"key":"5756_CR77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijcard.2017.01.009","volume":"232","author":"SJ Chou","year":"2017","unstructured":"Chou SJ, et al. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease. Int J Cardiol. 2017;232:255\u201363. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.009.","journal-title":"Int J Cardiol"},{"issue":"6","key":"5756_CR78","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","volume":"37","author":"JM Itier","year":"2014","unstructured":"Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014;37(6):1013\u201322. https:\/\/doi.org\/10.1007\/s10545-014-9724-5.","journal-title":"J Inherit Metab Dis"},{"issue":"52","key":"5756_CR79","doi-asserted-by":"publisher","first-page":"87161","DOI":"10.18632\/oncotarget.13552","volume":"7","author":"Y Chien","year":"2016","unstructured":"Chien Y, et al. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget. 2016;7(52):87161\u201379. https:\/\/doi.org\/10.18632\/oncotarget.13552.","journal-title":"Oncotarget"},{"issue":"2","key":"5756_CR80","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","volume":"13","author":"MJ Birket","year":"2019","unstructured":"Birket MJ, et al. A human stem cell model of Fabry disease implicates limp-2 accumulation in cardiomyocyte pathology. Stem Cell Reports. 2019;13(2):380\u201393. https:\/\/doi.org\/10.1016\/j.stemcr.2019.07.004.","journal-title":"Stem Cell Reports"},{"key":"5756_CR81","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae095","author":"T Klein","year":"2024","unstructured":"Klein T, et al. Small fibre neuropathy in Fabry disease: a human-derived neuronal in vitro disease model and pilot data. Brain Commun. 2024. https:\/\/doi.org\/10.1093\/braincomms\/fcae095.","journal-title":"Brain Commun"},{"key":"5756_CR82","unstructured":"Dietrich B, Karpinski N, Jakob M, Weidemann F, Breunig F, Wanner C, Ertl G, Bauersachs J, Thum T. Malfunction of endothelial progenitor cells and endothelial function in patients with Fabry disease.\u00a0J Stem Cells Regener Med. 2007;2(1):161\u20132."},{"issue":"3","key":"5756_CR83","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3727\/096368916X694265","volume":"26","author":"WL Tseng","year":"2017","unstructured":"Tseng WL, et al. Imbalanced production of reactive oxygen species and mitochondrial antioxidant SOD2 in fabry disease-specific human induced pluripotent stem cell-differentiated vascular endothelial cells. Cell Transplant. 2017;26(3):513\u201327. https:\/\/doi.org\/10.3727\/096368916X694265.","journal-title":"Cell Transplant"},{"issue":"4","key":"5756_CR84","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/cells8040327","volume":"8","author":"HY Song","year":"2019","unstructured":"Song HY, Chiou SH. Generation of GLA -Knockout human embryonic stem cell lines to model autophagic dysfunction. Cells. 2019;8(4):327.","journal-title":"Cells"},{"key":"5756_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100914","author":"CR Kaneski","year":"2022","unstructured":"Kaneski CR, Hanover JA, Schueler Hoffman UH. Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease. Mol Genet Metab Rep. 2022. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100914.","journal-title":"Mol Genet Metab Rep"},{"key":"5756_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.634190","author":"CS Chien","year":"2021","unstructured":"Chien CS, et al. Dual DNA transfection using 1,6-hexanedithiol-conjugated maleimide-functionalized PU-PEI600 for gene correction in a patient iPSC-derived Fabry cardiomyopathy model. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.634190.","journal-title":"Front Cell Dev Biol"},{"key":"5756_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040936","author":"BX Ho","year":"2018","unstructured":"Ho BX, Pek NMQ, Soh BS. Disease modeling using 3D organoids derived from human induced pluripotent stem cells. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19040936.","journal-title":"Int J Mol Sci"},{"key":"5756_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247125","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Organogenesisin a dish: modeling development and disease using organoid technologies. Science. 2014. https:\/\/doi.org\/10.1126\/science.1247125.","journal-title":"Science"},{"issue":"1","key":"5756_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-03992-0","volume":"21","author":"S Cui","year":"2023","unstructured":"Cui S, et al. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system. J Transl Med. 2023;21(1):1\u201312. https:\/\/doi.org\/10.1186\/s12967-023-03992-0.","journal-title":"J Transl Med"},{"issue":"15","key":"5756_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202103526","volume":"9","author":"JW Kim","year":"2022","unstructured":"Kim JW, et al. Kidney Decellularized extracellular matrix enhanced the vascularization and maturation of human kidney organoids. Advanced Science. 2022;9(15):1\u201318. https:\/\/doi.org\/10.1002\/advs.202103526.","journal-title":"Advanced Science"},{"key":"5756_CR91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2023.02.005","volume":"258","author":"S Cui","year":"2023","unstructured":"Cui S, et al. CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model. Transl Res. 2023;258:35\u201346. https:\/\/doi.org\/10.1016\/j.trsl.2023.02.005.","journal-title":"Transl Res"},{"issue":"12","key":"5756_CR92","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1007\/s00415-020-10044-w","volume":"267","author":"C Simoncini","year":"2020","unstructured":"Simoncini C, et al. Oxidative stress biomarkers in Fabry disease: is there a room for them? J Neurol. 2020;267(12):3741\u201352. https:\/\/doi.org\/10.1007\/s00415-020-10044-w.","journal-title":"J Neurol"},{"key":"5756_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jksus.2021.101710","author":"S Seidi","year":"2022","unstructured":"Seidi S, Eftekhari A, Khusro A, Heris RS, Sahibzada MUK, Gajd\u00e1cs M. Simulation and modeling of physiological processes of vital organs in organ-on-a-chip biosystem. J King Saud Univ Sci. 2022. https:\/\/doi.org\/10.1016\/j.jksus.2021.101710.","journal-title":"J King Saud Univ Sci"},{"key":"5756_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00174-y","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, et al. Organoids. Nat Rev Methods Primers. 2022. https:\/\/doi.org\/10.1038\/s43586-022-00174-y.","journal-title":"Nat Rev Methods Primers"},{"key":"5756_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302686","author":"H Liu","year":"2023","unstructured":"Liu H, Gan Z, Qin X, Wang Y, Qin J. \u2018Advances in microfluidic technologies in organoid research. Adv Healthc Mater. 2023. https:\/\/doi.org\/10.1002\/adhm.202302686.","journal-title":"Adv Healthc Mater"},{"issue":"7","key":"5756_CR96","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.bbamcr.2015.11.036","volume":"1863","author":"C Zuppinger","year":"2016","unstructured":"Zuppinger C. 3D culture for cardiac cells. Biochim Biophys Acta Mol Cell Res. 2016;1863(7):1873\u201381. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.11.036.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"5756_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2631","author":"E Mohr","year":"2022","unstructured":"Mohr E, Thum T, B\u00e4r C. Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models. John Wiley and Sons Ltd. 2022. https:\/\/doi.org\/10.1002\/ejhf.2631.","journal-title":"John Wiley and Sons Ltd"},{"key":"5756_CR98","doi-asserted-by":"publisher","unstructured":"Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proceed Nat Acad Sci U S A. 2001;98(5):2676\u201381. https:\/\/doi.org\/10.1073\/pnas.051634498.","DOI":"10.1073\/pnas.051634498"},{"key":"5756_CR99","doi-asserted-by":"publisher","unstructured":"Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.\u00a0Proceed Nat Acad Sci U S A.\u00a02002;99(21):13777\u201382. https:\/\/doi.org\/10.1073\/pnas.222221899.","DOI":"10.1073\/pnas.222221899"},{"key":"5756_CR100","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","volume":"18","author":"M Yasuda","year":"2020","unstructured":"Yasuda M, et al. AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction. Mol Ther Methods Clin Dev. 2020;18:607\u201319. https:\/\/doi.org\/10.1016\/j.omtm.2020.07.002.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5756_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02894-0","author":"M Deng","year":"2023","unstructured":"Deng M, et al. Systematic gene therapy derived from an investigative study of AAV2\/8 vector gene therapy for Fabry disease. Orphanet J Rare Dis. 2023. https:\/\/doi.org\/10.1186\/s13023-023-02894-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"5756_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30(6):487\u2013502. https:\/\/doi.org\/10.1038\/s41434-022-00381-y.","journal-title":"Gene Ther"},{"issue":"7","key":"5756_CR103","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nmeth.4304","volume":"14","author":"JA Bagley","year":"2017","unstructured":"Bagley JA, Reumann D, Bian S, L\u00e9vi-Strauss J, Knoblich JA. Fused cerebral organoids model interactions between brain regions. Nat Methods. 2017;14(7):743\u201351. https:\/\/doi.org\/10.1038\/nmeth.4304.","journal-title":"Nat Methods"},{"issue":"4","key":"5756_CR104","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41551-020-0539-4","volume":"4","author":"DJ Richards","year":"2020","unstructured":"Richards DJ, et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat Biomed Eng. 2020;4(4):446\u201362. https:\/\/doi.org\/10.1038\/s41551-020-0539-4.","journal-title":"Nat Biomed Eng"},{"key":"5756_CR105","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.biomaterials.2017.07.021","volume":"142","author":"DJ Richards","year":"2017","unstructured":"Richards DJ, et al. Inspiration from heart development: Biomimetic development of functional human cardiac organoids. Biomaterials. 2017;142:112\u201323. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.07.021.","journal-title":"Biomaterials"},{"issue":"13","key":"5756_CR106","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.7150\/thno.54999","volume":"11","author":"K Lu","year":"2021","unstructured":"Lu K, et al. Progressive stretch enhances growth and maturation of 3D stem-cell-derived myocardium. Theranostics. 2021;11(13):6138\u201353. https:\/\/doi.org\/10.7150\/thno.54999.","journal-title":"Theranostics"},{"key":"5756_CR107","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.actbio.2020.02.015","volume":"106","author":"SAP Rajan","year":"2020","unstructured":"Rajan SAP, et al. Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform. Acta Biomater. 2020;106:124\u201335. https:\/\/doi.org\/10.1016\/j.actbio.2020.02.015.","journal-title":"Acta Biomater"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05756-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05756-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05756-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:02:29Z","timestamp":1729774949000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05756-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5756"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05756-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT acknowledges support by Sanofi-Genzyme and Amicus Therapeutics (not for this MS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"965"}}